Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swapnil Rajpathak

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Diabetes, Obesity & Metabolism|December 20, 2018
Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United KingdomManjiri Pawaskar, S Pinar Bilir, Stacey Kowal, et al.
Current Medical Research and Opinion|March 31, 2017
Demographic and clinical profiles of type 2 diabetes mellitus patients initiating sitagliptin in the real-world settingManjiri Pawaskar, Jinan Liu, Swapnil Rajpathak, et al.
Diabetes, Obesity & Metabolism|June 16, 2021
Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United StatesXi Tan, Lingfeng Yang, Kamlesh Khunti, et al.
Current Medical Research and Opinion|September 1, 2020
Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium-glucose cotransporter 2 inhibitor: a retrospective database studyDominik Lautsch, Kristy Iglay, Lingfeng Yang, et al.
American Health & Drug Benefits|February 7, 2018
The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication UseYuexin Tang, Xingyue Huang, Jinan Liu, et al.
Drugs & Aging|April 24, 2013
Sulfonylureas and risk of falls and fractures: a systematic reviewKate L Lapane, Shibing Yang, Monique J Brown, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 5, 2018
Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes MellitusYuexin Tang, Jinan Liu, Hakima Hannachi, et al.
Frontiers in Endocrinology|October 31, 2022
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysisShangyu Chai, Ruya Zhang, Ye Zhang, et al.
Frontiers in Endocrinology|August 26, 2022
Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trialsShangyu Chai, Ruya Zhang, Ye Zhang, et al.
Journal of Clinical & Translational Endocrinology|February 26, 2020
Effects of conformance to type 2 diabetes guidelines on health care resource utilization, clinical outcomes, and cost: A retrospective claims analysisRajesh R Mehta, Alison M Edwards, Swapnil Rajpathak, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Diabetes, Obesity & Metabolism|December 20, 2018
Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United KingdomManjiri Pawaskar, S Pinar Bilir, Stacey Kowal, et al.
Current Medical Research and Opinion|March 31, 2017
Demographic and clinical profiles of type 2 diabetes mellitus patients initiating sitagliptin in the real-world settingManjiri Pawaskar, Jinan Liu, Swapnil Rajpathak, et al.
Diabetes, Obesity & Metabolism|June 16, 2021
Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United StatesXi Tan, Lingfeng Yang, Kamlesh Khunti, et al.
Current Medical Research and Opinion|September 1, 2020
Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium-glucose cotransporter 2 inhibitor: a retrospective database studyDominik Lautsch, Kristy Iglay, Lingfeng Yang, et al.
American Health & Drug Benefits|February 7, 2018
The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication UseYuexin Tang, Xingyue Huang, Jinan Liu, et al.
Drugs & Aging|April 24, 2013
Sulfonylureas and risk of falls and fractures: a systematic reviewKate L Lapane, Shibing Yang, Monique J Brown, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 5, 2018
Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes MellitusYuexin Tang, Jinan Liu, Hakima Hannachi, et al.
Frontiers in Endocrinology|October 31, 2022
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysisShangyu Chai, Ruya Zhang, Ye Zhang, et al.
Frontiers in Endocrinology|August 26, 2022
Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trialsShangyu Chai, Ruya Zhang, Ye Zhang, et al.
Journal of Clinical & Translational Endocrinology|February 26, 2020
Effects of conformance to type 2 diabetes guidelines on health care resource utilization, clinical outcomes, and cost: A retrospective claims analysisRajesh R Mehta, Alison M Edwards, Swapnil Rajpathak, et al.
Pageof 8